{"id":"rpv-drv-r","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Lipid abnormalities"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to and inhibits HIV reverse transcriptase, preventing conversion of viral RNA to DNA. Darunavir is a protease inhibitor that blocks HIV protease, preventing maturation of viral particles. Ritonavir is a pharmacokinetic booster that inhibits CYP3A4, increasing darunavir plasma concentrations. Together, this combination targets two critical steps in the HIV replication cycle.","oneSentence":"RPV (rilpivirine) and DRV/r (darunavir/ritonavir) are antiretroviral agents that inhibit HIV reverse transcriptase and protease, respectively, blocking viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:01.219Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment-experienced or treatment-naive patients)"}]},"trialDetails":[{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT04901728","phase":"","title":"Patients' Experiences and Perceptions of 3TC/DTG Dual Therapy (the PEDAL Study)","status":"UNKNOWN","sponsor":"University of Sussex","startDate":"2021-07-01","conditions":"HIV Infections","enrollment":118},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT01792570","phase":"PHASE3","title":"DRV/r + RPV QD: Efficacy and Toxicity Reduction","status":"COMPLETED","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2014-09-30","conditions":"Human Immunodeficiency Virus","enrollment":37},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00977756","phase":"","title":"IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2002-08","conditions":"HIV Infections","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RVP: rilpivirine; brand name: EdurantTM.","DRV: darunavir; brand name: PrezistaTM."],"phase":"phase_3","status":"active","brandName":"RPV + DRV/r","genericName":"RPV + DRV/r","companyName":"ASST Fatebenefratelli Sacco","companyId":"asst-fatebenefratelli-sacco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RPV (Rilpivirine) and DRV/r (Darunavir/Ritonavir) are antiretroviral medications used to treat HIV-1 infection, as indicated by ClinicalTrials.gov. However, the mechanism of action for RPV and DRV/r is unknown, according to ChEMBL.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}